Business
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files Patent for Preservative-Free Ketamine Formulation
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - May 6, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage bioph...
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.","length":145,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA - May 6, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP) a clinical-stage biopharma company, has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation targeting suicidal depression. The patent, which includes 20 claims, could provide exclusivity through 2045 if granted. NRX-100 is designed without benzethonium chloride or other preservatives linked to toxicity and has shown room temperature shelf stability - potentially qualifying it for FDA Orange Book listing. The filing supports the company's NDA submission strategy and complements the FDA Fast Track Designation of companion drug NRX-101.","length":668,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":"Investor Brand Network","className":"","disableSlideshowImg":false,"size":{"original":{"width":1400,"height":800,"url":"https://media.zenfs.com/en/newsmediawire_165/77406d7bdf01a94db7e00a8d5521cbef"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fg210KR9PDU4nlh34rkWVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0OTtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/77406d7bdf01a94db7e00a8d5521cbef","width":960,"height":549},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/x2ntO9Nh7wy0fJC4JhM0Ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzcyO2NmPXdlYnA-/https://media.zenfs.com/en/newsmediawire_165/77406d7bdf01a94db7e00a8d5521cbef","width":1200,"height":686}}},{"type":"text","content":"To view the full press release, visit https://ibn.fm/X8uSQ","length":58,"tagName":"p"},{"type":"text","content":"About NRx Pharmaceuticals, Inc.","length":31,"tagName":"p"},{"type":"text","content":"NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression...